| Sep 12 |
CNS Pharmaceuticals regains Nasdaq compliance
|
| Sep 12 |
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
|
| Sep 4 |
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Sep 3 |
IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.
|
| Aug 27 |
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
|
| Aug 22 |
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
|
| Aug 16 |
CNS Pharmaceuticals reports Q2 results
|
| Aug 15 |
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
|
| Jul 30 |
CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
|
| Jul 25 |
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference
|
